clinical trial · NCT06088199
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Plaque PsoriasisApremilast
brief summary
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
started
Oct 24, 2023
primary completion
Aug 12, 2026
completion
Aug 12, 2026
last updated
Aug 28, 2026
official title
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol